" class="no-js "lang="en-US"> Bing Yuan - Medtech Alert
Friday, April 03, 2026
Bing Yuan

Bing Yuan

About Bing Yuan

Seasoned biotech and pharmaceutical entrepreneur and business executive with 20+ years of experience. Honored to have the chance to help cancer patients by contributing to 13 globally approved oncology drugs at various stages of their life cycle (Gavreto, Tabrecta, Ayvakit, Tibsovo, Keytruda, Glivec, Afinitor, Jakavi, Zykadia, Mektovi, Kymriah, Halaven and Lenvima).

As a founding executive, helped to build CStone Pharmaceuticals from scratch to successful IPO in less than 3 years. Aspired to do it again for OnCusp Therapeutics with a different business model.

Related Story

OnCusp Therapeutics Commences Operations to Advance Innovative Oncology Therapies

June 30 2021

OnCusp Therapeutics (or “OnCusp”), a global biopharmaceutical company focused on translating cutting-edge research assets into […]